AMRN

Amarin Corporation plc (AMRN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Amarin Corporation plc is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA globally. The company operates in a single segment and has transitioned its European commercialization to a partnership model with Recordati Industria Chimica e Farmaceutica S.p.A. effective June 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 7% year-over-year, driven by a 6% increase in product revenue and an 84% increase in licensing/royalty revenue. U.S. product revenue remained flat ($35.6M), while non-U.S. product revenue grew significantly due to the new partnership model in Europe and growth in other territories.
• Gross Margin Compression: Gross margin percentage declined from 59% to 37%. Management attributes this to a change in customer mix, specifically the shift to selling to partners in Europe rather than direct sales, which typically carry lower net prices.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 42% to $21.1 million, primarily due to the Global Restructuring Plan initiated in June 2025 to eliminate commercial roles in Europe. Research and Development (R&D) expenses decreased 12% to $4.7 million.
• Restructuring Charges: The company recorded $3.3 million in restructuring expenses in Q1 2026, compared to none in Q1 2025. Cumulative charges since the plan's inception total $39.6 million.
• Cash Flow Improvement: Operating cash flow turned positive at $6.4 million, a significant improvement from the $12.5 million outflow in the prior year, driven by cost savings from restructuring.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue competitively managing market leadership in the U.S. and driving expanded access globally through partners. The company anticipates the Global Restructuring Plan will result in approximately $40.0 million in total charges, substantially all of which are cash expenditures.
• Legal Proceedings:
  • Antitrust Litigation: On April 14, 2026, the company agreed to a confidential settlement with indirect and direct purchaser plaintiffs regarding antitrust class action lawsuits. A negotiated settlement payment was recognized in SG&A expenses for Q1 2026.
  • Patent Litigation: The Supreme Court granted a petition to review the Federal Circuit's decision regarding patent infringement claims against Hikma. Oral arguments are scheduled for April 29, 2026.
  • Executive Litigation: Former CEO Karim Mikhail's lawsuit regarding constructive termination is ongoing, with a motion to dismiss deadline set for May 20, 2026.
• Generic Competition: The U.S. market faces competition from multiple generic versions of icosapent ethyl for the MARINE indication. However, VASCEPA's market share increased to approximately 48% in Q1 2026, up from 42% in the prior year.
• Liquidity: The company has no debt and maintains $307.8 million in cash and short-term investments, which management believes is sufficient to fund operations for at least one year.

Key Facts for Investor Verification

• Settlement Impact: Verify the specific amount of the antitrust settlement payment recognized in Q1 2026 SG&A expenses and its impact on future cash outflows.
• Margin Trajectory: Monitor whether the 37% gross margin stabilizes as the European partnership with Recordati matures and volume increases.
• Supreme Court Ruling: Track the outcome of the Hikma patent appeal scheduled for April 29, 2026, as it could impact the REDUCE-IT indication exclusivity.
• Restructuring Completion: Confirm the timeline for the completion of the $40 million Global Restructuring Plan and the realization of projected cost savings.
• Inventory Levels: Note the high inventory level of $183.6 million (35% approved for North America) and assess potential obsolescence risks given the generic landscape.